STAT+: At ASH, Terns looks like rival to Novartis with drug for chronic myeloid leukemia

This is the online version of ASH in 30 Seconds, STAT’s report from the American Society of Hematology meeting. Sign up for the email version here. 

It rains in Florida. A lot. This ASH meeting started sunny and wonderful, but quickly turned rainy and miserable. It’s just another reason why ASH should camp itself permanently in San Diego each December.

Study suggests Terns leukemia drug could be successor to Novartis blockbuster

Adam Feuerstein/STAT

Terns Pharmaceuticals reported an update on its targeted leukemia drug that maintained and even boosted high molecular response rates in advanced-stage patients.

Continue to STAT+ to read the full story…